Close
Novotech
Jabsco PureFlo 21 Single Use

Singapore Witnesses A $50mn Funding In Research & Innovation

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

How Mobile Field Hospitals Are Changing Emergency Care

Healthcare systems can collapse overnight, particularly in natural disasters...

How Automation Is Transforming Mail-Order Pharmacy Operations: Efficiency, Accuracy and ROI

This article includes: Expanding the Role of Mail-Order Pharmacies ...

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.
- Advertisement -

NUS Academic Medical Centre and SingHealth in Singapore have announced a gift of $50 million, which will be transformational, from the Lee Foundation that will aid in providing support for the advancement of research and innovation via programmes as well as initiatives across the AMC health discovery district—an ecosystem that will be complete with innovation centres that would connect the SingHealth campus, which includes the upcoming eastern general hospital as well.

The Academic Medicine Innovation Institute, which came into being in 2021, will look into the upbringing of a vibrant culture within the ecosystem.

This Lee Foundation gift will push the AMC’s vision to strengthen and design the frameworks in order to hasten the progress across healthcare innovation with pilot grants and funding, seed the potential for innovation and discovery, and also go all out when it comes to bringing out medicines with the help of new research programmes.

Chairman of SingHealth, Cheng Wai Keung pledged a $9 million support for ecosystem of dementia program in the National Neuroscience Institute. There were a total of 30 donors who contributed. The program, which is expected to launch in April 2023, looks to deliver key life-transforming services and also give out compassionate support across the care continuum for patients suffering from dementia as well as their families and caregivers, from screening to community care to intervention and rehabilitation.

Apart from this, the GK Goh family gave a gift of $5 million that was made in honour of the executive chairman and founder of GK Goh Holdings. The amount that is pledged will allow the establishment of proposed centre for neuroscience research which will help scientists from Duke-NUS to study the mechanisms behind the human brain ageing and the issues that underpin the degenerative disorders with the focus to developing effective novel therapeutics and also strategies in order to slow the process of ageing and take care of debilitating illnesses related to neuro.

Latest stories

Related stories

How Mobile Field Hospitals Are Changing Emergency Care

Healthcare systems can collapse overnight, particularly in natural disasters...

How Automation Is Transforming Mail-Order Pharmacy Operations: Efficiency, Accuracy and ROI

This article includes: Expanding the Role of Mail-Order Pharmacies ...

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »